Corporate Profile

We are a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we utilize a precision medicine approach to develop a pipeline of therapeutic candidates that we believe will activate and restore microglial function.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Jun 07, 2022
Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia
Jun 01, 2022
Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference
May 12, 2022
Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights
Events & Presentations
Print Page
Email Alerts
RSS Feeds
Contact IR

Exit

You are leaving Vigil Neuroscience, Inc.’s website. You may return to Vigil Neuroscience, Inc.’s website by using the “Back” button on your Web browser toolbar or closing the window to the third-party website that you have opened. Do you wish to continue?